Publications by authors named "Malika Saadi"
Article Synopsis
- - In 2022, France recorded 181,178 hospitalizations for heart failure (HF), yielding a prevalence rate of 2.6% among adults, while hospitalization rates were notably higher in socioeconomically deprived areas.
- - The overall hospital fatality rate for HF was 10.2%, with a significant increase to 34.0% within a year; however, only 20.1% of patients were admitted to rehabilitation within six months.
- - The findings highlight the need for improved cardiovascular prevention strategies and adaptations in healthcare services across different regions in France, emphasizing the importance of better adherence to treatment guidelines.
Objectives: Polypharmacy, drug-drug interactions (DDI) and related adverse drug reaction (ADR) are understudied in SSc. The aim of this work was to determine the prevalence and determinants of DDI and ADR in a real-life prospective cohort of SSc patients.
Methods: We performed a retrospective analysis of the drug prescriptions of SSc patients admitted to the daily scleroderma clinic between January 2020 and April 2022.
Background: Patent foramen ovale (PFO) is causally associated with stroke in some patients younger than 60 years, especially when it is large or associated with an atrial septal aneurysm (ASA). After 60 years of age, this association is less well understood. We assessed the relationships between detailed atrial septal anatomy and the cryptogenic nature of stroke in this population.
View Article and Find Full Text PDFPurpose: Remote patient monitoring (RPM) can improve the management of chronic diseases. Since 2019, RPM in chronic heart failure (CHF) management has been internationally supported. However, evidence on the clinical impact and good practices of RPM is scarce.
View Article and Find Full Text PDFArticle Synopsis
- Patients with mitochondrial diseases are at a higher risk for heart failure (HF) and serious heart-related events, prompting the creation of prediction models to estimate these risks.
- In a study involving 600 adult patients, over 6.67 years, 4.9% developed HF, and 5.1% experienced arrhythmic major adverse cardiac events (MACE).
- Key predictors for these heart issues included specific genetic variants, heart structure changes, and reduced heart function as indicated by low ejection fractions.*
Synthetized by the liver and metabolized by the gut microbiota, BA are involved in metabolic liver diseases that are associated with cardiovascular disorders. Animal models of atheroma documented a powerful anti-atherosclerotic effect of bile acids (BA). This prospective study examined whether variations in circulating BA are predictive of coronary artery disease (CAD) in human.
View Article and Find Full Text PDFArticle Synopsis
- The American College of Cardiology/American Heart Association suggests ACE inhibitors (ACE-i) for patients with non-ischemic cardiomyopathy when their left ventricular ejection fraction (LVEF) drops below 40%.
- This study investigates whether starting ACE-i treatment earlier, at an LVEF below 50%, leads to better long-term heart health outcomes in patients with Becker muscular dystrophy cardiomyopathy compared to the standard practice.
- Results show that patients receiving early ACE-i treatment had significantly lower rates of hospitalization for heart failure and less severe decreases in LVEF, indicating improved cardiac outcomes compared to those starting treatment with LVEF below 40%.
Aims: To estimate the effect of prophylactic angiotensin-converting enzyme inhibitors (ACEi) on survival in Duchenne muscular dystrophy (DMD).
Methods And Results: We analysed the data from the French multicentre DMD Heart Registry (ClinicalTrials.gov: NCT03443115).